Abstract
The most important aspect of therapy with fluoride and tamoxifen concerns its influence on bone tissue and lipid metabolism. The aim of the study was to evaluate the effect of tamoxifen and natrium fluoride (NaF) on bone metabolism, biochemical properties and blood lipids levels in ovariectomized rats. The study was performed in Wistar rats divided into 5 subgroups: ovariectomized controls, rats treated with NaF 20 mg/kg/24 hr, rats treated with NaF 20 mg/kg/24 hr+tamoxifen 2 mg/kg/24 hr, rats treated with NaF 20 mg/kg/24 hr plus tamoxifen 4 mg/kg/24 hr, and sham-operated controls. In ovariectomized rats the increase of total cholesterol, low-density lipoproteins cholesterol (LDL-cholesterol) as well as the decrease of bone mineral content, bone mineral density and biomechanical properties was observed. The therapy with NaF increased the level of total cholesterol, LDL-cholesterol, triglycerides, bone mineral density, bone mineral content. In this group the decrease of bone strength and stiffness was observed. The administration of tamoxifen reduced the changes in plasma lipid levels, but did not improve the biomechanical properties of bone tissue.
-
-
Drinking water fluoridation: bone mineral density and hip fracture incidence
The role of drinking water fluoride content for prevention of osteoporosis remains controversial. Therefore, we analyzed the influence of drinking water fluoridation on the incidence of osteoporotic hip fractures and bone mineral density (BMD) in two different communities in eastern Germany: in Chemnitz, drinking water was fluoridated (1 mg/L) over
-
The relationship of bone mass and fracture history to fluoride and calcium intake: a study of three communities
Stimulated by the suggestion that water fluoride greater than 1 mg/L may protect against osteoporosis, we studied bone mass of women in three rural communities with differing mineral content of the water supply. Mean fluoride and calcium of community drinking waters were 4 mg/L and 16 mg/L, respectively, high fluoride
-
Osteoporosis Treatments Affect Bone Matrix Maturation in a Rat Model of Induced Cortical Remodeling.
The example of sodium fluoride (NaF) clearly demonstrates an instance where increasing bone mass while altering maturation can negatively affect drug efficacy. NaF was a promising osteoporosis treatment because it increased BMD.5 However, it became evident that the treated patients were at increased risk of fracture,6, 7 which was later
-
Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial
OBJECTIVE: To test whether slow-release sodium fluoride inhibits spinal fractures and is safe to use. DESIGN: Placebo-controlled randomized trial. INTERVENTIONS: Slow-release sodium fluoride, 25 mg twice daily, in four 14-month cycles (12 months receiving sodium fluoride followed by 2 months not receiving it) compared with placebo. Calcium citrate, 400 mg calcium twice daily, continuously in
-
Fluoride Salts are no Better at Preventing New Vertebral Fractures than Calcium-Vitamin D in Postmenopausal Osteoporosis: The FAVOStudy.
Although fluoride salts have been shown to be capable of linearly increasing spinal bone mineral density (BMD) in postmenopausal osteoporosis, the effects of this gain in density on the vertebral fracture rate remain controversial. We conducted a 2-year multicenter, prospective, randomized, double-masked clinical trial in 354 osteoporotic women with vertebral
Related Studies :
-
-
-
Fluoride in Water & Bone Fracture
Current epidemiological evidence indicates that the margin of safety between the level of fluoride in water that does, and does not, increase the risk of fracture is insufficiently large to protect all members of society from fluoride-induced damage to bone.
-
"Pre-Skeletal" Fluorosis
As demonstrated by the studies below, skeletal fluorosis may produce adverse symptoms, including arthritic pains, clinical osteoarthritis, gastrointestinal disturbances, and bone fragility, before the classic bone change of fluorosis (i.e., osteosclerosis in the spine and pelvis) is detectable by x-ray. Relying on x-rays, therefore, to diagnosis skeletal fluorosis will invariably fail to protect those individuals who are suffering from the pre-skeletal phase of the disease. Moreover, some individuals with clinical skeletal fluorosis will not develop an increase in bone density, let alone osteosclerosis, of the spine. Thus, relying on unusual increases in spinal bone density will under-detect the rate of skeletal fluoride poisoning in a population.
-
Clinical Trials: Fluoride Treatment & Bone Fracture in Osteoporosis Patients
Due to its ability to increase bone mass, fluoride has been used as an experimental treatment for osteoporosis. The results, however, have generally been disastrous. Rather than prevent bone fractures in osteoporosis patients, fluoride therapy (at doses of 20-34 mg/day) was repeatedly found to increase fracture rates. One of the most
-
Fluoride & Spontaneous Hip Fractures in Osteoporosis Patients
Due to its ability to increase vertebral bone mass, fluoride has been used as an experimental treatment for osteoporosis (doses > 20 mg/day). Fluoride treatment, however, proved far more harmful than beneficial. Not only was fluoride therapy shown to increase fracture rates among the treated patients, it was also found to
-
In Vitro Studies on Fluoride & Bone Strength
The "in vitro" research on fluoride and bone strength confirms what has repeatedly been found in animal and human studies: the more fluoride a bone has, the weaker the bone becomes. In an in vitro bone study, the researcher directly exposes a human or animal bone to a fluoride solution
Related FAN Content :
-